This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Vortioxetine

Well Researched

Multimodal serotonergic antidepressant — SERT inhibition + 5-HT3 antagonist + 5-HT7 antagonist + 5-HT1B partial agonist + 5-HT1A agonist. FDA-approved 2013 for MDD with the strongest pro-cognitive (DSST processing speed + executive function) signal of any antidepressant in head-to-head trials.

Aliases (4)

Trintellix · Brintellix · Lu AA21004 · vortioxetine hydrobromide

TYPICAL DOSE

10 mg/day (range 5-20 mg)

Daily

ROUTE

Oral (tablet)

Oral tablet

CYCLE

No formal cycling — designed for steady-state d…

No cycling

STORAGE

Room temp; original container

Room temp

Overview

What is Vortioxetine?

Vortioxetine (Trintellix in the US since 2016, originally Brintellix 2013-2016 — renamed due to confusion with the antiplatelet drug Brilinta) is a multimodal serotonergic antidepressant FDA-approved 2013 for major depressive disorder. Internal code Lu AA21004; marketed by Lundbeck/Takeda. Distinct from any other antidepressant in mechanism.

Key Benefits

Antidepressant efficacy with the strongest pro-cognitive signal of any modern antidepressant in head-to-head trials (FOCUS, CONNECT) — improves Digit Symbol Substitution Test (DSST) processing speed and executive function in MDD with cognitive symptoms, partially independent of mood improvement. Lower sexual dysfunction than SSRIs. Long half-life (~66 hours) is forgiving of missed doses. Lower discontinuation syndrome risk than SSRIs/SNRIs.

Mechanism of Action

Multimodal serotonergic action: serotonin transporter (SERT) inhibition (~50% occupancy at 5 mg, ~80% at 20 mg) PLUS 5-HT3 receptor antagonism (drives nausea but disinhibits cortical glutamate + acetylcholine release) PLUS 5-HT7 antagonism (improves cognition + reduces sexual dysfunction) PLUS 5-HT1B partial agonism PLUS 5-HT1A agonism. The receptor-modulating activity is not pharmacokinetic noise — it produces measurable downstream effects on cortical glutamate, acetylcholine, dopamine, and norepinephrine that no pure SSRI achieves.

Pharmacokinetics

PeakHalf-life

Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

SERT inhibition

primary serotonin transporter blockade. ~50% occupancy at 5 mg, ~80% at 20 mg (vs SSRIs which routinely sit >80%). Lower SERT saturation …

Effective

5-HT3 antagonist

blocks cortical 5-HT3 inhibition of GABAergic interneurons → disinhibits cortical glutamate and acetylcholine release. Mechanistic basis …

Investigational

5-HT7 antagonist

implicated in cognition (working memory, learning) and reduced sexual dysfunction. Antagonism appears to be the differentiator vs pure SS…

Investigational

5-HT1B partial agonist

modulates serotonergic and dopaminergic terminals.

Investigational

5-HT1A full agonist

autoreceptor downregulation effect similar to buspirone-class anxiolytics.

Peptide Interactions

MAOIs (selegiline >10 mg, tranylcypromine, phenelzine, linezolid, methylene blue):

Avoid

contraindicated, 14-day washout each direction.

Other SSRIs / SNRIs:

Avoid

redundant SERT load, serotonin syndrome risk in cross-titration.

5-HTP, L-tryptophan, St John's wort:

Avoid

serotonergic stack.

Tramadol, meperidine, fentanyl, dextromethorphan high-dose:

Avoid

serotonergic opioids.

Triptans (sumatriptan etc.):

Avoid

FDA class warning; clinical risk likely low but monitor.

Strong CYP2D6 inhibitors:

Avoid

dose adjustment required (halve).

Anticoagulants / chronic NSAIDs:

Avoid

modestly increased bleeding risk.

Quality Indicators

✓

Pharmacy-dispensed, intact packaging

Trintellix (US) or Brintellix (legacy/ex-US) tablets in original sealed packaging from a licensed pharmacy.

Generic availability

First US generics launched 2024-2025 after patent expiry; verify NDC and manufacturer if switching from branded Trintellix.

✗

Unbranded blister or counterfeit risk

Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.

What to Expect

Week 1
Tolerability and dose-response.
Week 2-4
Early effect window.
Week 4-8
Peak benefit assessment.
Week 8+
Cycle decision point.

Side Effects & Safety

Common (>10%): Nausea (20-30% across trials, peaks week 1), dose-dependent. Constipation, dry mouth.
Less common (1-10%): Diarrhea, dizziness, sexual dysfunction (lower than SSRIs but still ~5-10%), abnormal dreams, vomiting.
Rare-serious (<1%): Serotonin syndrome (especially with serotonergic combos), abnormal bleeding (SERT inhibition impairs platelet 5-HT release), hyponatremia, suicidal ideation <25 yo (FDA black box class warning), mania switch in undiagnosed bipolar.
Specific watch periods: First 4 weeks for activation/suicidality (class warning <25 yo), week 1 for nausea, weeks 2-8 for sexual function check.